Dogwood Therapeutics, Inc.
DWTX
NASDAQ·Healthcare·Biotechnology·Mkt cap $77.0M
$2.29
▼ -2.14%
P/E
—
Mkt Cap
$77.0M
52-Wk Range
$1.28–$9.50
52-Week Range
$1.28 - $9.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 53.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Novel fixed-dose combination approach targeting viral-immune dysfunction
- First-mover advantage in treating fibromyalgia with antiviral-based therapy
- Experienced management team with biotechnology expertise
- Addressing large unmet medical needs with limited current treatment options
Bear Case
1 risk
- Above-average volatility (beta 1.8).
Growth
Stable outlook
Clinical trial progression for IMC-1 fibromyalgia indication
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+56.9% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying DWTX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 13, 2026
Reported EPS of -$0.34 vs -$0.14 consensus (-142.9% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-142.9%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Sep 2, 2026
vs Industry
How DWTX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related